green tick

Pfizer settles majority of US Champix cases

0 comments Read Later

Pfizer settles majority of US Champix cases

Pfizer has settled more than 80 per cent of the more than 2700 US lawsuits filed against it involving the smoking cessation drug Chantix (varenicline), which is known as Champix in Australia.

In a statement to the US Securities and Exchange Commission, Pfizer reported that it had recorded aggregate charges in 2012 of approximately US $273 million (AUS$234 million), in relation to the settlements for the cases which were files in US federal and state courts.

The company added that addition charges may be required in the future in connection to pending actions and claims relating to the drug.

“The federal Chantix actions were consolidated in the MDL more than three years ago, and the unresolved Chantix federal and state actions and other known, unresolved Chantix claims could take many more years to resolve,” Pfizer said in its statement to the Securities and Exchange Commission.

“However, opportunistic settlements could occur at any time. The litigation process is time consuming, as every Chantix action being litigated involves contested issues of medical causation and knowledge of risk.”

A spokesperson for Pfizer Australia told Pharmacy News that the company does not comment on matters that are before the court.


 Subscribe to our Newsletter

 Breaking news and special features
 A daily must-read for pharmacists
 Delivered to your inbox
By filling in your email address and clicking submit with this option selected, you agree to receive email communications from us relevant to the healthcare industry. You always have the option of unsubscribing later via an unsubscribe link or your subscriptions management page. View our privacy policy here.

Your profile is
0% complete


Pharmacy News on Twitter


My list
Read Later